Ikuo Hirano1, Evan S Dellon2, Jennifer D Hamilton3, Margaret H Collins4, Kathryn Peterson5, Mirna Chehade6, Alain M Schoepfer7, Ekaterina Safroneeva8, Marc E Rothenberg4, Gary W Falk9, Yehudith Assouline-Dayan10, Qiong Zhao3, Zhen Chen3, Brian N Swanson11, Gianluca Pirozzi11, Leda Mannent12, Neil M H Graham3, Bolanle Akinlade3, Neil Stahl3, George D Yancopoulos3, Allen Radin3. 1. Northwestern University Feinberg School of Medicine, Chicago, Illinois. Electronic address: i-hirano@northwestern.edu. 2. Center for Esophageal Diseases and Swallowing, University of North Carolina School of Medicine, Chapel Hill, North Carolina. 3. Regeneron Pharmaceuticals, Inc, Tarrytown, New York. 4. Cincinnati Children's Hospital Medical Center and University of Cincinnati College of Medicine, Cincinnati, Ohio. 5. University of Utah School of Medicine, Salt Lake City, Utah. 6. Mount Sinai Center for Eosinophilic Disorders, Icahn School of Medicine at Mount Sinai, New York, New York. 7. Centre Hospitalier Universitaire Vaudois et Université de Lausanne, Lausanne, Switzerland. 8. Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland. 9. University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania. 10. University of Iowa Hospitals and Clinics, Iowa City, Iowa. 11. Sanofi, Bridgewater, New Jersey. 12. Sanofi, Chilly-Mazarin, France.
Abstract
BACKGROUND & AIMS:Eosinophilic esophagitis (EoE) is an allergen-mediated inflammatory disease with no approved treatment in the United States. Dupilumab, a VelocImmune-derived human monoclonal antibody against the interleukin (IL) 4 receptor, inhibits IL4 and IL13 signaling. Dupilumab is effective in the treatment of allergic, atopic, and type 2 diseases, so we assessed its efficacy and safety in patients with EoE. METHODS: We performed a phase 2 study of adults with active EoE (2 episodes of dysphagia/week with peak esophageal eosinophil density of 15 or more eosinophils per high-power field), from May 12, 2015, through November 9, 2016, at 14 sites. Participants were randomly assigned to groups that received weekly subcutaneous injections of dupilumab (300 mg, n = 23) or placebo (n = 24) for 12 weeks. The primary endpoint was change from baseline to week 10 in Straumann Dysphagia Instrument (SDI) patient-reported outcome (PRO) score. We also assessed histologic features of EoE (peak esophageal intraepithelial eosinophil count and EoE histologic scores), endoscopically visualized features (endoscopic reference score), esophageal distensibility, and safety. RESULTS: The mean SDI PRO score was 6.4 when the study began. In the dupilumab group, SDI PRO scores were reduced by a mean value of 3.0 at week 10 compared with a mean reduction of 1.3 in the placebo group (P = .0304). At week 12, dupilumab reduced the peak esophageal intraepithelial eosinophil count by a mean 86.8 eosinophils per high-power field (reduction of 107.1%; P < .0001 vs placebo), the EoE-histologic scoring system (HSS) severity score by 68.3% (P < .0001 vs placebo), and the endoscopic reference score by 1.6 (P = .0006 vs placebo). Dupilumab increased esophageal distensibility by 18% vs placebo (P < .0001). Higher proportions of patients in the dupilumab group developed injection-site erythema (35% vs 8% in the placebo group) and nasopharyngitis (17% vs 4% in the placebo group). CONCLUSIONS: In a phase 2 trial of patients with active EoE, dupilumab reduced dysphagia, histologic features of disease (including eosinophilic infiltration and a marker of type 2 inflammation), and abnormal endoscopic features compared with placebo. Dupilumab increased esophageal distensibility and was generally well tolerated. ClinicalTrials.gov, Number: NCT02379052.
RCT Entities:
BACKGROUND & AIMS:Eosinophilic esophagitis (EoE) is an allergen-mediated inflammatory disease with no approved treatment in the United States. Dupilumab, a VelocImmune-derived human monoclonal antibody against the interleukin (IL) 4 receptor, inhibits IL4 and IL13 signaling. Dupilumab is effective in the treatment of allergic, atopic, and type 2 diseases, so we assessed its efficacy and safety in patients with EoE. METHODS: We performed a phase 2 study of adults with active EoE (2 episodes of dysphagia/week with peak esophageal eosinophil density of 15 or more eosinophils per high-power field), from May 12, 2015, through November 9, 2016, at 14 sites. Participants were randomly assigned to groups that received weekly subcutaneous injections of dupilumab (300 mg, n = 23) or placebo (n = 24) for 12 weeks. The primary endpoint was change from baseline to week 10 in Straumann Dysphagia Instrument (SDI) patient-reported outcome (PRO) score. We also assessed histologic features of EoE (peak esophageal intraepithelial eosinophil count and EoE histologic scores), endoscopically visualized features (endoscopic reference score), esophageal distensibility, and safety. RESULTS: The mean SDI PRO score was 6.4 when the study began. In the dupilumab group, SDI PRO scores were reduced by a mean value of 3.0 at week 10 compared with a mean reduction of 1.3 in the placebo group (P = .0304). At week 12, dupilumab reduced the peak esophageal intraepithelial eosinophil count by a mean 86.8 eosinophils per high-power field (reduction of 107.1%; P < .0001 vs placebo), the EoE-histologic scoring system (HSS) severity score by 68.3% (P < .0001 vs placebo), and the endoscopic reference score by 1.6 (P = .0006 vs placebo). Dupilumab increased esophageal distensibility by 18% vs placebo (P < .0001). Higher proportions of patients in the dupilumab group developed injection-site erythema (35% vs 8% in the placebo group) and nasopharyngitis (17% vs 4% in the placebo group). CONCLUSIONS: In a phase 2 trial of patients with active EoE, dupilumab reduced dysphagia, histologic features of disease (including eosinophilic infiltration and a marker of type 2 inflammation), and abnormal endoscopic features compared with placebo. Dupilumab increased esophageal distensibility and was generally well tolerated. ClinicalTrials.gov, Number: NCT02379052.
Authors: Ian F Slack; Justin T Schwartz; Vincent A Mukkada; Shawna Hottinger; J Pablo Abonia Journal: Curr Allergy Asthma Rep Date: 2020-06-06 Impact factor: 4.806
Authors: Ikuo Hirano; Edmond S Chan; Matthew A Rank; Rajiv N Sharaf; Neil H Stollman; David R Stukus; Kenneth Wang; Matthew Greenhawt; Yngve T Falck-Ytter Journal: Ann Allergy Asthma Immunol Date: 2020-05 Impact factor: 6.347
Authors: Matthew A Rank; Rajiv N Sharaf; Glenn T Furuta; Seema S Aceves; Matthew Greenhawt; Jonathan M Spergel; Yngve T Falck-Ytter; Evan S Dellon Journal: Ann Allergy Asthma Immunol Date: 2020-05 Impact factor: 6.347